JENNY OLALEYE

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care MANSFIELD, TX NPI 1467039677

General Payments — all program years on this page

$3,340.73

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 140
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $829.15 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $554.2119
Travel and Lodging $274.941

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2021 $792.7247
2022 $1,081.6246
2023 $637.2427
2024 $829.1520

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087231011 Novartis Pharmaceuticals Corporation $26.85 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087231029 Novartis Pharmaceuticals Corporation $32.26 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087231045 Novartis Pharmaceuticals Corporation $34.68 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101284318 E.R. Squibb & Sons, L.L.C. $22.05 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105457638 AstraZeneca Pharmaceuticals LP $21.60 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105569539 AstraZeneca Pharmaceuticals LP $21.18 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114351555 Regeneron Healthcare Solutions, Inc. $33.60 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115980145 Amgen Inc. $22.38 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118019168 Boehringer Ingelheim Pharmaceuticals, Inc. $18.53 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131102395 PFIZER INC. $24.80 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131347561 PFIZER INC. $15.83 03/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131515623 PFIZER INC. $14.21 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131930246 PFIZER INC. $21.07 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132309220 SCPHARMACEUTICALS INC. $15.45 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133855537 CVRx, Inc. $24.87 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133855539 CVRx, Inc. $274.94 10/17/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1133855541 CVRx, Inc. $107.03 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1138768266 Edwards Lifesciences Corporation $36.18 07/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1138768344 Edwards Lifesciences Corporation $39.38 11/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141903760 Merck Sharp & Dohme LLC $22.26 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.